Wells Fargo initiated coverage of NewAmsterdam Pharma (NAMS) with an Overweight rating and $45 price target The firm believes cholesteryl ester transfer protein inhibition represents an “exciting new frontier” for lipid lowering and a multibillion dollar opportunity. NewAmsterdam has built obicetrapib on the foundations of four prior CETP inhibitors in the industry and the ongoing PREVAIL study is set up for success, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- NewAmsterdam Pharma’s EMA Validation for Obicetrapib
- NewAmsterdam announces acceptance of MAA for review by EMA for obicetrapib
- NewAmsterdam Pharma Signs Supply Agreement with Menarini
- Promising Future for NewAmsterdam Pharma: Buy Rating Backed by Strong Financials and Positive Trial Data
- NewAmsterdam Pharma Reports Q2 2025 Financial Results